4dmedical Ltd. · ASX:4DX
4dmedical — Investor Presentation (February 2025)
31 slides from 4dmedical's investor presentation, Feb 28, 2025
Slide 1: See beyond the structure
See beyond the structure 4DMedical Limited (ASX:4DX) Investor presentation 28 February 2025 Copyright ©4DMedical Limited 2025 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia ABN 31 161 684 831 www.4dmedical.com
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as of 28
Slide 3: Company updates and capital raising
Company updates and capital raising January 2025 U.S. FDA clearance for IQ-UIP, an AI-driven diagnostic tool designed to improve the diagnosis of Usual Interstitial Pneumonia (UIP), a key indicator of Interstitial Pulmonary Fibrosis (IPF), serving global market of US$4bn in 2024, expected to be US
Slide 4: 4DMedical 1H FY2025 Highlights
4DMedical 1H FY2025 Highlights
Slide 5: Recent achievements and momentum validate commercialisation strategy
Recent achievements and momentum validate commercialisation strategy FDA approval and new contracts Philips Expansion of product suite with FDA Master Reseller approval for IQ-UIP Expansion in AU Agreement US Department of executed Defense continued US Qscan and Perth Implementation engage
Slide 6: 4DMedical SaaS revenue building momentum
4DMedical SaaS revenue building momentum 4DMedical SaaS revenue – 1H24 to 1H251 Underlying 1H25 v 2H24 growth up 16.5% 4DMedical SaaS revenue ($M AUD) +16.5% • SaaS revenue growth of 10% refers to revenue 3.5 generated from SaaS contracts to radiology clinics and medical centres (AU and US). +10% 3.
Slide 7: SaaS revenue momentum from growth in sites, scans and fees
4DMedical SaaS revenue building momentum, driven by increased fundamentals of layering growth in sites, scans and fees Sites are growing at 41% YoY basis, with Scan volumes per site growing taking scan volume growth to 77% YoY, layered with increased fee per scan in core XV Technology® Site growth –
Slide 8: Net operating expenditure down 11% 1H25 vs 2H24
4DMedical net operating expenditure down 11% 1H25 vs 2H24, driven by strong focus on reallocation of resources to commercialisation 4DMedical net operating expenditure – 1H25 vs 2H241 -11% 21.2 Net Operating expenditure down 11% vs prior half1 18.8 • Strong focus on cost control and deployment of re
Slide 9: Regulatory clearance – product portfolio
Regulatory clearance – product portfolio Product Regulatory Clearance US Canada Europe Australia XV LVAS® Dynamic Ventilation Analysis (Fluoroscopy) Pulmonary Function CT LVAS CT-based Ventilation Analysis CT:VQ Next Gen VQ (Ventilation + Perfusion) – clearance yet to be submitted Function
Slide 10: Capital raise summary
Capital raise summary1 4DMedical is raising up to ~$12.5m via a Placement and Underwritten SPP • $5.5m Placement, offered at $0.425, represents a 22.7% discount to the last close of $0.55 on 20 February 2025 Placement • 12.9m new shares issued, utilising the Company’s available placement capacity un
Slide 11: Indicative Timetable
Indicative Timetable Indicative Placement and SPP timetable Event Date SPP record date Thursday, 20 February 2025 Announcement of Capital Raising Friday, 21 February 2025 SPP Opens Tuesday, 25 February 2025 Settlement of Placement Thursday, 27 February 2025 Allotment and normal trading of Placement
Slide 12: 4DMedical Overview
4DMedical Overview
Slide 13: Company highlights
Company highlights Proprietary XV Technology: Non-invasive, four-dimensional lung imaging technology that provides unparalleled insights into lung function Innovative Technology Differentiated from traditional imaging methods (e.g., X-ray, CT, MRI) by delivering detailed functional data, not jus
Slide 14: Global respiratory diagnostic market valued at US$31.3 billion per annum
Global respiratory diagnostic market valued at US$31.31 billion per annum Four existing lung diagnostic technologies account for 99% of all lung tests: Country Spend Procedures ($USD) Expenditure (USD $B) U.S.A 13,716M 73.5M 20 Others 4,964M 59.8M Germany 2,678M 20.3M Japan 1,905M 22.8M 15 Procedure
Slide 15: Current lung diagnostics are failing us
Current lung diagnostics are failing us Lung health screening Unexplained dyspnoea Burn Pits & DRRD (COPD, silicosis, black lung, lung cancer) (shortness of breath) (Deployment-related Respiratory Disease) COPD – 4th largest cause of $12.2bn cost of breathlessness in Australia2 >6million servi
Slide 16: Ventilation Perfusion
Ventilation Perfusion playback 0.85x (14 breaths per minute) playback 0.48x (75 beats per minute) 4DMedical Limited (ASX:4DX) 28 February 2025
Slide 17: Comprehensive chest diagnostics product suite
Comprehensive chest diagnostics product suite CT LVAS 1 XV LVAS 1 CT:VQ 5 Pulmonary Hypertension XV Scanner^ VA Initiatives Assessment 1,4 Functional Coronary Lung Density Artery Analysis 1,4 Calcification 1 XV Technology Partnerships Lung Density Analysis — Lung Texture Inspiration 1,4 Analysis 2,4
Slide 18: A Complete Lung Health Solution
A Complete Lung Health Solution Pulmonary Function Pulmonary Structure Cardiovascular Total Solution XV LVAS®1,4 CAC1,2 Combined product Lung Density 1,2,4 Dynamic Ventilation Emphysema, HAA, Fissures Coronary Calcification/Heart suite Analysis (Fluoroscopy) Disease Enabling access to key imaging mo
Slide 19: Commercialisation strategy
Commercialisation strategy US Government US Commercial Global Partnerships Australia Enablers Olympus I-Med Exclusive Non-exclusive Genentech Jones Radiology Reimbursement Nuance/Aidoc/Blackford Integral Diagnostics Sector Veterans Affairs Community-based Clinics Global Pharma Companies Community Cl
Slide 20: US and Philips opportunity
US and Philips opportunity
Slide 21: US reimbursement – XV LVAS, CT LVAS and now IQ-UIP
US reimbursement – XV LVAS®, CT LVAS and now IQ-UIP 1 We addressed three key 2 We engaged with key 3 CMS reimbursement was components of industry bodies for approved reimbursement support and approval American Medical Association Clinical data Code – describing the procedure CPT Panel and Adviso
Slide 22: Boosting Clinical Insights From Chest Imaging With Reimbursed Studies
Boosting Clinical Insights From Chest Imaging With Reimbursed Studies Identification of UIP patterns (Quantitative CT) $650.50 (Hospital Outpatient) 0877T & 0878T 4DMedical Limited (ASX:4DX) 28 February 2025 22
Slide 23: Philips reseller agreement activated
Philips reseller agreement activated The reseller agreement The opportunity • Philips has a long established and significant existing 1 partnership with both the VA and DoD, spanning 45 years • Philips & 4DMedical to work together to Background support the need for scalable, non-invasive • 50% of VA
Slide 24: Introduction to CT:VQ
Introduction to CT:VQ
Slide 25: CT:VQ has an immediate opportunity to displace NUC:VQ
CT:VQ has an immediate $1.1B $2.6B NUC:VQ - USA NUC:VQ - GLOBAL opportunity to + organic growth displace NUC: VQ + organic growth through superior access through enhanced access (and grow Reimbursed study Superior economics considerably through uptake on CT) 4DMedical Limited (ASX:4DX) 28 February 2
Slide 26: NUC:VQ is plagued by logistical and technical challenges
SPECT (V) SPECT (Q) NUC:VQ is plagued by logistical and technical challenges • Nuclear VQ is slow, logistically complex, expensive & delivers low resolution results. • This multi billion-dollar procedure is ripe for disruption. 26
Slide 27: CT:VQ — Comparison to SPECT Ventilation and Perfusion
CT:VQ — Comparison to SPECT Ventilation and Perfusion CT:VQ images correlate to SPECT with superior image fidelity without logistical challenges SPECT (V) CT:VQ (V) SPECT (Q) CT:VQ (Q) 27 Product is for investigational/research use only in a clinical study, is not regulatory approved and is not avai
Slide 28: CT:VQ vs Nuclear Perfusion in COPD
CT:VQ vs Nuclear Perfusion in COPD CT:VQ images correlate to SPECT with superior image fidelity without logistical challenges Nuclear Perfusion CT:VQ Perfusion Good visual alignment despite different scans and analysis technology 28 Product is for investigational/research use only in a clinical stud
Slide 29: Existing technology plagued by logistical and technical challenges
Existing technology plagued by logistical and technical challenges NUCLEAR MEDICINE CT:VQ – PROVIDING ENHANCED CURRENT STATE PATIENT EXPERIENCE AND EFFICIENCIES HIGH-COST PROCEDURE CT:VQ FOCUSES ON ADDRESSING THREE CRITICAL ISSUES: 1 ENHANCED PHYSICIAN EXPERIENCE POOR RESOLUTION OF OUTPUTS 1. REDUCI
Slide 30: Built the fundamentals, significant multipliers in play during 2025
Built the fundamentals, significant multipliers in play during 2025 Foundations Multiplier #1 Multiplier #2 ….2025 2026…. established Philips agreement CT:VQ displacing NUC:VQ Commercialisation of comprehensive lung function 25 x >$1b portfolio established, with >$6m run-rate Key opinion leaders
Slide 31: 4DMedical Limited (ASX:4DX)
4DMedical Limited (ASX:4DX) 28 February 2025 Copyright © 4DMedical Limited 2025 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831